

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/548,089	09/06/2005	Maki Iwahashi	Q90022	2099
23373	7590 09/19/2006		EXAMINER	
SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W.			KOSACK, JOSEPH R	
SUITE 800			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20037			1626	

DATE MAILED: 09/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/548,089	IWAHASHI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Joseph Kosack	1626				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timused and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) ■ Responsive to communication(s) filed on 17 Fe 2a) ■ This action is FINAL. 2b) ■ This 3) ■ Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
4) ⊠ Claim(s) 1-22,24 and 25 is/are pending in the a 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-22,24 and 25 are subject to restriction	vn from consideration.	,				
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the lidenating on be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	4) ☐ Interview Summary Paper No(s)/Mail Do 5) ☐ Notice of Informal F	ate				
Paper No(s)/Mail Date 6) Other:						

Art Unit: 1626

DETAILED ACTION

Claims 1-22 and 24-25 are pending in the instant application.

Election/Restrictions

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Due to the numerous variables in the claims, e.g. R¹, R², R³, R⁴, A, etc... and their widely divergent meanings, a precise listing of inventive groups cannot be made. The following groups are exemplary:

Group I, claim(s) 1-19 and 21 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein: A is carbonyl and ring 1 is phenyl.

Group II, claim(s) 1-19 and 21 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein: A is carbonyl and ring 1 is 2-pyridyl.

Group III, claim(s) 1-19 and 21 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein: A is carbonyl and ring 1 is 1,2-oxazole-3-yl.

Group IV, claim(s) 1-19 and 21 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein: A is carbonyl and ring 1 is 1,3-thiazole-2-yl.

Group V, claim(s) 1-19 and 21 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein: A is sulfone and ring 1 is phenyl.

Group VI, claim(s) 1-19 and 21 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein: A is sulfone and ring 1 is phenyl.

Group VII, claim(s) 11-19 and 21 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein: A is sulfone and ring 1 is phenyl.

Art Unit: 1626

Group VIII, claim(s) 1-19 and 21 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein: A is sulfone and ring 1 is phenyl.

Group IX, claim(s) 20, 22, and 24-25, are drawn to pharmaceutical compositions with intended uses and methods of use of compounds of Formula I.

In accordance with 37 CFR 1.499, Applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. Again, this list is not exhausted, as it would be impossible under the time constraints due to the sheer volume of subject matter instantly claimed. Therefore, Applicant may choose to elect a single invention by identifying another specific embodiment not listed in the exemplary groups of the invention and Examiner will endeavor to group the same. If Applicant is unable to elect a single invention, Applicant may instead choose to elect a specific compound and Examiner will attempt to group it. The claims herein lack unity of invention under PCT Rule 13.1 and 13.2 since the compounds defined in the claims lack a significant structural element qualifying as the special technical feature that defines a contribution over the prior art. The compounds claimed contain a core structure of a substituted indole ring system, which does not define a contribution over the prior art (see WO 01/66520 A1). The substituents vary extensively and when taken as a whole result in vastly different compounds. Accordingly, unity of invention is considered to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered proper. Additionally, the vastness of the claimed subject matter and the complications in understanding the claimed subject matter imposes a

Application/Control Number: 10/548,089

Art Unit: 1626

burden on any examination of the claimed subject matter. The method of use claims will be examined with the elected invention commensurate in scope therewith.

A telephone call was made to Mark Boland on September 7, 2006 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Kosack whose telephone number is (571)-272-5575. The examiner can normally be reached on M-F 5:30 A.M. until 2:00 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph M^cKane can be reached on (571)-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/548,089

Art Unit: 1626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patent Examiner

Art Unit 1626

Joseph K. MºKane

Supervisory Patent Examiner

Page 5

Art Unit 1626